Lilly jumps 6.6% on Q3 beat as analysts lift targets

Eli Lilly and Company delivered its Q3 results on October 29, closing the day at $1,373.70, a 6.6% single-session gain that extended the stock's one-month rise to 16%. Within hours of the print, four analyst firms raised their price targets, with the highest new target sitting at $1,612.

Analysts reprice in unison

The post-earnings response from the Street was immediate. Truist Securities raised its target from $1,376 to $1,612, reiterating Buy. RBC Capital moved from $1,500 to $1,600, maintaining Outperform. Argus Research lifted from $1,300 to $1,550. Wells Fargo raised from $1,330 to $1,500, maintaining Overweight. All four actions landed on October 30, the session after the print. The consensus mean target now stands at $1,361.50, though several of the fresh targets already sit well above that figure as the broader consensus catches up.

The bull case entering the quarter centred on Mounjaro and Zepbound momentum offsetting weakness in older drugs. The bear case flagged missed expectations in Verzenio, Taltz, and Trulicity, with the latter's prescriptions running more than 20% below year-ago levels for a third consecutive quarter. The stock's reaction suggests the market weighted the incretin strength more heavily than the legacy drag.

Options hedgers caught on the wrong side

Before the print, put/call positioning reached 1.29, nearly 2.5 standard deviations above its 20-day average of 1.19. That peak defensive reading proved poorly timed. The stock's 6.6% gain on earnings day means much of the put protection bought in the final sessions before results expired worthless or sharply out of the money. The PCR has now been elevated for five consecutive sessions, a run that began when the ratio stood at 1.19 and escalated daily into the close.

Borrow costs spike, but the lending pool is wide open

Cost to borrow surged to 0.42% by October 29, up 253% over the prior week. That is a notable move in percentage terms. In absolute terms it remains low: availability is effectively uncapped, with shares available to lend vastly exceeding the roughly 7.4 million shares currently held short. Short interest is 0.82% of the free float, down 11.5% over the past month. There is no crowded short. The CTB spike reflects episodic pre-earnings borrow demand, not structural pressure on the stock from the short side.

Public attention hits a three-sigma peak

Retail attention reached 3.06 standard deviations above its own 90-day average on October 30, measured by English Wikipedia article views and ORTEX page traffic. That reading reflects the earnings event drawing a broader audience to the stock, not a sustained shift in consumer interest. It corroborates the volume of activity around the print rather than pointing to any independent signal.

• Close Oct 29: $1,373.70, up 6.6% on the day, up 16% over one month
• Analyst targets raised Oct 30: Truist $1,612, RBC $1,600, Argus $1,550, Wells Fargo $1,500
• Put/call ratio: 1.29 on Oct 29, 2.46 standard deviations above 20-day mean
• Cost to borrow: 0.42%, up 253% week-on-week; lending availability remains effectively uncapped
• Short interest: 0.82% of free float, down 11.5% over 30 days
• Retail attention: 3.06 standard deviations above 90-day average (Wikipedia views and ORTEX traffic, as of Oct 30)